Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Retirement Systems of Alabama

Retirement Systems of Alabama increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 165,445 shares of the biopharmaceutical company’s stock after purchasing an additional 728 shares during the period. Retirement Systems of Alabama’s holdings in Halozyme Therapeutics were worth $6,115,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of HALO. Artisan Partners Limited Partnership lifted its stake in shares of Halozyme Therapeutics by 3.4% in the 3rd quarter. Artisan Partners Limited Partnership now owns 7,712,874 shares of the biopharmaceutical company’s stock worth $294,632,000 after acquiring an additional 253,363 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Halozyme Therapeutics by 0.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,698,359 shares of the biopharmaceutical company’s stock worth $64,877,000 after acquiring an additional 15,902 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of Halozyme Therapeutics by 174.5% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company’s stock worth $33,894,000 after acquiring an additional 563,989 shares during the period. Kennedy Capital Management LLC lifted its stake in shares of Halozyme Therapeutics by 4.7% in the 3rd quarter. Kennedy Capital Management LLC now owns 646,475 shares of the biopharmaceutical company’s stock worth $24,695,000 after acquiring an additional 28,880 shares during the period. Finally, Principal Financial Group Inc. lifted its stake in shares of Halozyme Therapeutics by 10.9% in the 3rd quarter. Principal Financial Group Inc. now owns 590,651 shares of the biopharmaceutical company’s stock worth $22,563,000 after acquiring an additional 58,123 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $39.91 on Friday. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89. The stock has a market cap of $5.07 billion, a P/E ratio of 18.91, a PEG ratio of 0.47 and a beta of 1.26. The company has a 50-day moving average of $39.99 and a two-hundred day moving average of $37.89. Halozyme Therapeutics, Inc. has a 12-month low of $29.85 and a 12-month high of $45.00.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The business had revenue of $230.04 million for the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. As a group, research analysts predict that Halozyme Therapeutics, Inc. will post 3.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on HALO. Benchmark restated a “buy” rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. JMP Securities reiterated a “market outperform” rating and issued a $72.00 price target on shares of Halozyme Therapeutics in a report on Wednesday, February 21st. StockNews.com upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. The Goldman Sachs Group cut their price target on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a report on Thursday, January 18th. Finally, TheStreet downgraded shares of Halozyme Therapeutics from a “b-” rating to a “c+” rating in a report on Monday, January 22nd. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $53.29.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $38.49, for a total transaction of $384,900.00. Following the completion of the transaction, the senior vice president now owns 168,176 shares in the company, valued at $6,473,094.24. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders sold 30,000 shares of company stock worth $1,196,800. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.